Eli Lilly and Company (LLY) Shares Sold by Wagner Bowman Management Corp
Wagner Bowman Management Corp lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,078 shares of the company’s stock after selling 227 shares during the period. Wagner Bowman Management Corp’s holdings in Eli Lilly and were worth $1,240,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Bridges Investment Counsel Inc. acquired a new stake in shares of Eli Lilly and during the second quarter worth about $751,000. Cedar Wealth Management LLC increased its stake in shares of Eli Lilly and by 9.0% in the second quarter. Cedar Wealth Management LLC now owns 6,572 shares of the company’s stock worth $541,000 after buying an additional 540 shares during the period. Altfest L J & Co. Inc. increased its stake in shares of Eli Lilly and by 140.7% in the second quarter. Altfest L J & Co. Inc. now owns 16,848 shares of the company’s stock worth $1,387,000 after buying an additional 9,848 shares during the period. Farmers & Merchants Investments Inc. increased its stake in shares of Eli Lilly and by 1.7% in the second quarter. Farmers & Merchants Investments Inc. now owns 46,359 shares of the company’s stock worth $3,815,000 after buying an additional 760 shares during the period. Finally, Investment House LLC increased its stake in shares of Eli Lilly and by 3.8% in the second quarter. Investment House LLC now owns 33,477 shares of the company’s stock worth $2,755,000 after buying an additional 1,230 shares during the period. Hedge funds and other institutional investors own 75.59% of the company’s stock.
Shares of Eli Lilly and Company (NYSE LLY) traded down 0.05% during mid-day trading on Wednesday, reaching $81.67. The company’s stock had a trading volume of 720,136 shares. The firm’s 50-day moving average price is $82.77 and its 200 day moving average price is $81.92. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The firm has a market cap of $86.16 billion, a P/E ratio of 35.34 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the business posted $0.86 EPS. The company’s revenue was up 7.8% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.55%. Eli Lilly and’s dividend payout ratio is presently 90.04%.
TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Sold by Wagner Bowman Management Corp” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/16/eli-lilly-and-company-lly-shares-sold-by-wagner-bowman-management-corp.html.
A number of equities analysts recently weighed in on LLY shares. Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. BMO Capital Markets reissued a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a report on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the sale, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by company insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.